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Summary 
HIM-1 Rev protein directs nuclear export of pre-mRNAs 
and mRNAs containing its binding site, the Rev re- 
sponse element (RRE). To define how Rev acts, we 
used conjugates between bovine serum albumin (BSA) 
and peptides comprising the Rev activation domain 
(BSA-R). BSA-R inhibited Rev-mediated nuclear RNA 
export, whereas a mutant activation domain peptide 
conjugate did not. BSA-R did not affect the export of 
mRNA, tRNA, or ribosomal subunits, but did inhibit 
export of 5S rRNA and spliceosomal U snRNAs. BSA-R 
was itself exported from the nucleus in an active, satu- 
rable manner. Thus, the Rev activation domain consti- 
tutes a nuclear export signal that redirects RRE- 
containing viral RNAs to a non-mRNA export pathway. 
Introduction 
Cellular RNA species as diverse as messenger RNA 
(mRNA), transfer RNA (tRNA), ribosomal RNA (rRNA), 
and spliceosomal small nuclear RNAs (snRNAs) are ex- 
ported from the nucleus to the cytoplasm by an active, 
factor-mediated process. Although all molecules exit the 
nucleus via the nuclear pore complex, evidence has been 
provided that different factors mediate the export of spe- 
cific RNA classes (reviewed by Izaurralde and Mattaj, 
1995). Since most, if not all, RNAs associate with proteins 
in the cell nucleus, it is believed that RNA export is proba- 
bly mediated by specific proteins that harbor appropriate 
export signals. For example, the export of 5S rRNA from 
the Xenopus laevis oocyte nucleus is inhibited when the 
RNA is mutated so that it can interact with neither tran- 
scription factor TFIIIA nor ribosomal protein L5 (Guddat 
et al., 1990). Similarily, heterogenous nuclear ribonucleo- 
proteins (hnRNPs) such as A1 might be involved in the 
export of mRNAs since PiSoI-Roma and Dreyfuss (1991, 
1992) have shown that they shuttle constantly between 
the nuclear and cytoplasmic compartments. Factors that 
bind to the mTG cap structure are important for the export 
of the U1, U2, U4, and U5 spliceosomal snRNAs (Jarmo- 
:l:Present address: Department ofBiochemistry, Katholieke Universi- 
teit Nijmegen, 6500 HB Nijmegen, The Netherlands. 
Iowski et al., 1994). A nuclear mTG cap-binding complex 
that is involved in the export of these RNAs has been 
characterized (Hamm and Mattaj, 1990; Izaurralde et al., 
1992, 1994, 1995; reviewed by Izaurralde and Mattaj, 
1995). So far, however, there is no clear indication of how 
these proteins might mediate nuclear export. 
Export of RNAs has to be integrated with their pro- 
cessing. In the case of cellular pre-mRNAs, removal of 
introns by splicing is a prerequisite for export, and binding 
of spliceosomal factors actively retains pre-mRNA in the 
nucleus. Only after splicing is completed is the mature 
mRNA exported (Legrain and Rosbash, 1989). In contrast, 
complex retroviruses such as human immunodeficiency 
virus type 1 (HIV-1) require the export of not only fully 
spliced mRNA but also unspliced and partially spliced viral 
mRNA (reviewed by Cullen, 1992). Early in the HIV-1 repli- 
cation cycle, only fully spliced viral mRNA coding for the 
regulatory proteins Tat, Rev, and Nef accumulates in the 
cytoplasm. Later in infection, the incompletely spliced and 
unspliced late viral mRNAs also enter the cytoplasm. This 
temporal coordination of viral mRNA nuclear export is fa- 
cilitated by the RNA-binding Rev protein and its binding 
site, the Rev response element (RRE) (Feinberg et al., 
1986; Emerman et al., 1989; Felber et al., 1989; Malim et 
al., 1989a; Chang and Sharp, 1989). The RRE is present 
in all unspliced and partially spliced HIV-1 mRNA species 
but is eliminated from fully spliced viral mRNAs. 
Rev has at least two distinct functions. The amino-ter- 
minal domain has been shown to be necessary and suffi- 
cient for RRE binding, Rev multimerization, and nuclear 
translocation (Malim et al., 1989a; Malim and Cullen, 1991 ; 
Berger et al., 1991). A second domain, termed the activa- 
tion or effector domain, is believed to interact with one 
or more cellular factors required for Rev function since 
missense mutations in this region result in a trans-dom- 
inant negative phenotype (Malim et al., 1989b, 1991; Mer- 
mer et al., 1990; Venkatesh and Chinnadurai, 1990). 
Other complex retroviruses, such as human T cell lym- 
phopathic virus type I (HTLV-I) or equine infectious anemia 
virus, encode functionally equivalent proteins that are re- 
quired for the production in the cytoplasm of u nspliced viral 
RNA. The best characterized is the HTLV-I Rex protein 
(reviewed by Cullen, 1992). Simpler retroviruses, like Ma- 
son-Pfizer monkey virus, appear to use cellular proteins 
to achieve the same functional end (Bray et al., 1994). 
Two main models for Rev function have been proposed. 
One is that Rev may inhibit splicing or interfere with the 
assembly of the spliceosome. This hypothesis would imply 
that inhibiting spliceosome assembly would release pre- 
mRNA for transport o the cytoplasm. Evidence in support 
of this idea has been provided (Chang and Sharp, 1989; 
Kjems et al., 1991; Kjems and Sharp, 1993; Stutz and 
Rosbash, 1994). Alternatively, Rev might directly target 
viral pre-mRNA to the cytoplasm (Emerman et al., 1989; 
Felber et al., 1989; Malim et al., 1989a, 1989b; Malim and 
Cullen, 1993; Fischer et al., 1994a). Consistent with this 
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view, Rev does not change the ratio between unspliced 
and spliced viral RNA in transfected cells but rather in- 
duces a pattern of cytoplasmic viral RNA that mirrors the 
pattern seen in cell nuclei in the absence of Rev (Malim 
et al., 1989a, 1989b; Malim and Cullen, 1993). Addition- 
ally, Rev was able directly to promote nuclear export of 
RRE-containing mRNAs after nuclear injection into Xeno- 
pus oocytes independently of the presence of introns in 
these RNAs and thus presumably in the absence of 
spliceosome formation (Fischer et al., 1994a). 
The evidence summarized above suggested that a cellu- 
lar factor facilitates the export of unspliced viral mRNA by 
interacting with the activation domain of Rev. We have 
tested this model and show here that bovine serum albu- 
min (BSA) conjugates containing the Rev activation do- 
main in the form of peptides are capable of inhibiting Rev- 
mediated export of RRE-containing RNAs, implying that 
this domain interacts with a cellular factor that is a compo- 
nent of a nuclear export system. Moreover, peptides de- 
rived from the activation domain are sufficient o induce 
the nuclear export of BSA via an active and saturable path- 
way, defining the activation domain as a nuclear export 
signal (NES). Further competition studies suggest that 
Rev allows RRE-containing RNAs to enter an export path- 
way that is distinct from that used by cellular mRNAs. 
Results 
Specific Saturation of Rev-Mediated RNA Export by 
a Peptide Comprising the Rev Activation Domain 
To analyze whether Rev interacts with an essential imiting 
factor while exporting RRE-containing RNA, we searched 
for a specific competitor of Rev function. In analogy to 
experiments carried out with nuclear localization signal 
peptides (Goldfarb et al., 1986), we cross-linked a peptide 
consisting of the activation domain of the Rev protein to 
BSA (BSA-R, peptides CLPPLERLTL)(Figure 1A). Each 
molecule of BSA-R carried roughly 20 peptides (data not 
shown). To test whether a putative Rev-interacting factor 
would be titrated by BSA-R, we studied the Rev-mediated 
export of an RRE-containing RNA (pAd46 RNA; Fischer 
et al., 1994a) in the absence or presence of BSA-R. In the 
absence of Rev, pAd46 RNA is only slowly exported to 
the cytoplasm (Fischer et al., 1994a). When coinjected 
into oocyte nuclei with Rev protein, a2P-labeled pAd46 
RNA was mostly exported within 60 min (Figure 1B, lanes 
1 and 2). In contrast, in the presence of 10 I~g/p.I coinjected 
BSA-R, almost 90% of the injected pad46 RNA was still 
in the nucleus after 60 rain (compare lanes 1 and 2 with 
lanes 3 and 4 in Figure 1B). The export inhibition by BSA-R 
is time and concentration dependent, as shown by releas- 
ing inhibition after a longer incubation or by varying the 
concentration of the BSA-R competitor (Figure 1B, lanes 
3-6; data not shown). The BSA-R competitor does not 
interfere with the binding of Rev to the RRE in vitro (data 
not shown). 
Next, a peptide comprising the activation domain of the 
inactive Rev mutant M10 (Malim et al., 1989b) was cross- 
linked to BSA (BSA-M, peptides CLPPDLRLTL) (Figure 
A 
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Figure 1, Rev-Mediated Export Is a Saturable and Hence a Mediated 
Process 
(A) BSA conjugates used in this study. BSA-R consists of BSA and 
peptides encompassing the Rev activation domain. The peptide of 
BSA-M harbors a two amino acid substitution described in Malim et 
al, (1989a). 
(B) mTG-capped 32P-labeled pad46 was injected with a 20-fold molar 
excess of Rev into the nucleus of oocytes either without competitor 
(lanes 1 and 2) or with a 10 mg/ml solution of BSA-R (lanes 3 and 4) 
or BSA-M (lanes 7 and 8) competitor. Lanes 5 and 6 show an experi- 
ment in which BSA-R was injected at a concentration of 1 mg/ml. The 
nuclear export of pAd46 RNA was analyzed 60 rain later, Oocytes 
were incubated at 20°C before being dissected into nuclear (N) and 
cytoplasmic (C) fractions. RNA from both compartments was extracted 
and separated on a denaturing polyacrylamide gel. The injected RNA 
was detected by autoradiography. 
1A). BSA-M did not inhibit he export of pAd46 RNA (Figure 
1B, lanes 7 and 8), indicating that the observed export 
inhibition by BSA-R was specific and mirrored the function 
of the Rev activation domain. These data strongly suggest 
that the Rev activation domain interacts with a limiting 
cellular factor and that this interaction is necessary for its 
export activity. 
As a further control of specificity, we made use of pep- 
tides derived from the HTLV-I regulatory protein Rex. Rev 
and Rex appear to be functionally equivalent, although 
their primary sequences differ considerably (Rimsky et al., 
1988). In particular, previous studies have shown that the 
activation domains of Rex and Rev are interchangeable 
(Rimsky et al., 1988; Weichselbraun et al., 1992). 
BSA-Rex (peptides CMDALSAQLYSSLSLDSPPSPP) 
was prepared and coinjected with pAd46 RNA and Rev 
protein into the nucleus of oocytes. The BSA-Rex conju- 
gate inhibited the nuclear export of pAd46 RNA with an 
efficiency similar to that of BSA-R (Figure 2, lanes 9-12 
and 13-16). 
The Rev Activation Domain Is an NES 
To obtain more insight into the mode of action of the BSA-R 
conjugate, we examined its localization. Rev has been 
shown to shuttle rapidly between the nucleus and the cyto- 
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Figure 2. BSA Conjugated with Peptides Derived from HTLV-1 Rex 
Activation Domain Cross-Competes with Rev-Mediated Export 
32P-labeled pAd46 RNA was coinjected with a 20-fold molar excess 
of Rev into the nucleus of oocytes either without competitor (lanes 
1-4) or with a 10 mg/ml solution of BSA-R (lanes 5-8), BSA-M (lanes 
9-12), or BSA-Rex (lanes 13-16) competitor. The nuclear export of 
pAd46 RNA was analyzed 2 and 4 hr later. 
plasm. This depends on an intact activation domain and 
also on the separate nuclear localization signal of Rev. 
BSA-R or BSA-M was labeled with 12~1. The proteins were 
injected into the nuclei of oocytes, and their distribution 
between the nucleus and the cytoplasm was followed over 
a period of I hr (Figure 3; note that the cross-linking proce- 
dure induces some protein oligomerization). While BSA-M 
(as well as BSA or BSA conjugated with the inverse activa- 
tion domain peptide; data not shown; see also Mandell 
and Feldherr, 1990) remained entirely in the nucleus after 
2 hr (Figure 3A, lanes 3 and 4), BSA-R entered the cyto- 
plasm at a rate similar to that exhibited by RRE-containing 
RNAs in the presence of Rev (Figure 3A, lanes 1 and 2; 
Figure 3B, lanes 1-6). Nuclear export of BSA-R was, how- 
ever, severely inhibited when the oocytes were incubated 
at 4°C (Figure 3B, lanes 11 and 12). Thus, the Rev activa- 
tion domain acts as an NES, able to direct the export of 
a protein to which it is attached to the cytoplasm in a tem- 
perature-dependent manner. The export of BSA-R was 
not affected by coinjecting a40-fold excess of BSA-M com- 
petitor (Figure 3A, lanes 7 and 8), but was strongly reduced 
by the same amount of BSA-R (Figure 3A, lanes 5 and 6). 
The inhibition of BSA-R export by BSA-R competitor was 
concentration and time dependent (Figure 3B, lanes 
7-10; data not shown). Thus, export saturation by BSA-R 
is highly specific and dependent on the presence of an 
intact Rev activation domain. 
The NES Also Mediates the Export of BSA 
in Human Somatic Cells 
Since Rev normally exerts its RNA export-promoting func- 
tion in HIV-l-infected human cells, we analyzed whether 
the Rev NES was also functionally active in human so- 
matic cells. To test this, we labeled BSA-R and BSA-M 
conjugates with two different fluorescent dyes and injected 
them into HeLa cell nuclei. After a 1 hr incubation, localiza- 
tion was analyzed by fluorescence microscopy. BSA-R 
(stained green) was exported to the cytoplasm, while 
BSA-M (stained red) remained almost entirely in the nu- 
clear compartment (Figure 4A). Therefore, BSA-R and 
BSA-M exhibited the same behavior in HeLa cells as in 
oocytes. 
Export of BSA-R was again temperature dependent (Fig- 
ure 4B) and specifically saturable by an excess of unla- 
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r - - i  . . . . .  
N C N C N C N C 
1 2 3 4 5 6 7 8  
BSA-R/M 
B +BSA-R , 
0 rain 30 min 60 min high low 4°C 
N C N C N C N C N C N C 
- BSA-R 
1 2 3 4 5 6 7 8 9 10 11 12 
Figure 3. The HIV-1 Activation Domain Peptide Targets BSA to the 
Cytoplasm 
(A) 12Sl-labeled BSA-R (lanes 1 and 2) or BSA-M (lanes 3 and 4) (0.25 
mg/ml each) was injected into the nucleus of oocytes alone, or BSA-R 
was injected with either a 40-fold molar excess of unlabeled BSA-R 
(lanes 5 and 6) or BSA-M (lanes 7 and 8). Export was examined 2 hr 
later by protein extraction from nuclear (N) and cytoplasmic (C) frac- 
tions and by analysis on SDS-polyacrylamide gels. 
(B) Nuclear export of iodinated BSA-R was analyzed ir:nmediately after 
injection (lanes 1 and 2) or after 30 min (lanes 3 and 4) and 60 min 
(lanes 5 and 6). Lanes 7-10 show nuclear export after 60 min of iodin- 
ated BSA-R in the presence of a 40-fold (lanes 7 and 8) or 4-fold (lanes 
9 and t0) molar excess of unlabeled BSA-R or at 4°C (lanes 11 and 12). 
beled BSA-R (Figure 4C) but not BSA-M (Figure 4D). Inter- 
estingly, the nuclear BSA-R was found predominantly in 
the nucleoplasm. The nucleoli of these cells were devoid 
of label. The interaction between the NES and the cellular 
export factor is therefore not likely to occur in the nucleolus 
even though Rev appears to accumulate there. 
Rev-Mediated Export and Cellular mRNA Export 
Require Different Limiting Factors 
The above observations allowed a comparison of Rev- 
mediated RNA export and cellular mRNA export path- 
ways. A possible mode of Rev action is to overcome the 
retention in the nucleus caused by the presence of a 
spliceosome on a pre-mRNA, thereby facilitating access 
of the pre-mRNA to the cellular mRNA export pathway. If 
this were the case, the saturation of the Rev-mediated 
export pathway by injection of BSA-R would also be ex- 
pected to inhibit mRNA export. To test this, we analyzed 
in X. laevis oocytes the export of the pAd48 pre-mRNA 
and the products derived from it by splicing, pAd48 is a 
truncated adenovirus 2 major late transcription unit that 
consists of the first (L1) and second (L2) leader exons and 
a portion of intron 1 into which the RRE has been inserted 
(Fischer et al., 1994a). pAd48 pre-mRNA is efficiently 
spliced in oocytes. Because the pre-mRNA and the ex- 
cised intron lariat contain the RRE, they are efficiently 
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Figure 4. Nuclear Export of Fluorescently La- 
beled BSA-R in HeLa Cells 
HeLa cell nuclei were injected with a mixture 
of BSA-R and BSA-M (A) or with BSA-R alone 
(B). In (C) and (D), fluorescently abeled BSA-R 
was coinjected into he nucleus with a 20-fold 
molar excess of unlabeled BSA-R and BSA-M, 
respectively. Cells were incubated for 1 hr at 
37°C (A, C, and D) or 4°C (B), fixed, and 
analyzed by fluorescence microscopy as de- 
scribed in Experimental Procedures. Scale 
bar, 5 #m. 
exported upon binding to Rev. They are, however, like 
cellular pre-mRNAs and excised introns, retained in the 
nucleus in the absence of Rev. The spliced mRNA product 
does not contain an RRE and is exported independently 
of the presence of Rev (Fischer et al., 1994a). 
In vitro transcribed pAd48 pre-mRNA was injected into 
the nucleus of oocytes along with Rev protein and either 
BSA-R or, as a control, BSA-M. Export and splicing were 
then analyzed 1, 3, and 6 hr later. The injection of the 
BSA-M peptide had no effect on the kinetics of Rev- 
mediated export of RRE-containing RNA species (Figure 
5A; see also Figure 1B). However, coinjection of BSA-R 
strongly inhibited the export of the excised RRE-contain- 
ing intron lariat (Figure 5A). In contrast, the export rate of 
the spliced mRNA product was not affected by the pres- 
ence of BSA-R competitor (Figure 5A). Because the mRNA 
does not contain the RRE, it is presumably exported to 
the cytoplasm by means of the mRNA export pathway. 
The inhibition of export by BSA-R is therefore specific for 
the RRE-containing RNAs whose export is mediated by 
Rev, in this case the pre-mRNA and the intron lariat. 
To clarify whether the inability of BSA-R to inhibit cellular 
mRNA export was a general phenomenon, we examined 
the transport of an mRNA without introns, namely the 
mRNA coding for dihydrofolate reductase, DHFR (Jarmo- 
Iowski et al., 1994). As a control, we coinjected RRE- 
containing pAd46 RNA. In the absence of Rev, pAd46 
RNA is exported like an mRNA, but its export rate can be 
greatly stimulated by Rev (Fischer et al., 1994a). Initially, 
32P-labeled DHFR and pAd46 RNAs were injected into the 
nucleus of oocyt es along with Rev, and their nuclear export 
was analyzed 1 hr and 4 hr later (Figure 5B). Both DHFR 
and pAd46 RNAs were largely exported to the cytoplasm 
within 4 hr (Figure 5B, lanes 1-4). When BSA-R was coin- 
jected, the export of pAd46 mRNA was efficiently inhibited 
in a concentration- and time-dependent manner (Figure 
5B, lanes 5-8; data not shown). In contrast, there was no 
difference in the export kinetics of the DHFR mRNA after 
coinjection with either BSA-R or BSA-M (Figure 5B, lanes 
5-12). 
These data strongly suggest that the cofactor required 
for Rev-dependent RNA export is not required for the ex- 
port of cellular mRNA to the cytoplasm. We next asked 
whether limiting factors required for the export of cellular 
mRNA were also required for Rev-mediated export. To 
analyze this possibility, we tested whether saturation of 
the mRNA export pathway by injection of an excess of 
mRNA competitor had any effect on the kinetics of Rev- 
mediated export. For this experiment, two 32P-labeled 
mRNAs without introns, DHFR RNA and pAd46 RNA, were 
coinjected. Both were exported in the absence of Rev. 
However, pAd46 RNA is unstable in the cytoplasm, and 
after 2 hr, much of the exported pAd46 RNA was degraded 
(Figure 6, lanes 1-4). The export of both 32P-labeled DHFR 
and pAd46 RNAs were efficiently inhibited in the presence 
of an excess of unlabeled DHFR mRNA competitor. In this 
case, the pAd46 RNA remained in the nucleus and was 
stable (Figure 6, lanes 5-8). Thus, in the absence of Rev, 
both RNAs were exported to the cytoplasm by means of 
the mRNA export pathway. Next, DHFR and pAd46 RNAs 
were injected into the nucleus with a 10-fold molar excess 
of Rev protein. Again, injections were carried out either 
with or without an excess of unlabeled competitor mRNA. 
Both RNAs were transported to the cytoplasm in the ab- 
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Figure 5. Saturation of the Rev-Mediated RNA Export Does Not Affect 
the Export of mRNA 
(A) mTG-capped pAd48 pre-mRNA was injected along with a 20-fold 
molar excess of Rev protein and a 10 mg/ml solution of either BSA-R 
or BSA-M into the nucleus of oocytes. To control whether the injection 
occurred into the nucleus only, we coinjected 32P-labeled U6 snRNA. 
Oocytes were incubated for 1, 3, and 6 hr, and nuclear export was 
analyzed as in Figure 1. Abbreviations: M, marker; N, nucleus; C, 
cytoplasm; L, intron lariat. 
(B) A mixture of 32P-labeled in vitro transcribed and m~G-capped DHFR 
mRNA and pad46 RNA was injected into the nucleus of oocytes along 
with a 20-fold molar excess of Rev protein and either water (lanes 
1-4) or a 10 mg/ml solution of BSA-R (lanes 5-8) or BSA-M (lanes 
9-12). Nuclear export was analyze das described in Figure 1. Abbrevia- 
tions: N, nuclear; C, cytoplasmic. 
sence of competitor with comparable xport kinetics. The 
export of DHFR mRNA was unaffected by the presence 
of Rev, while the pAd46 RNA export rate was enhanced 
(compare lanes 1-4 with lanes 9-12 in Figure 6). In the 
presence of the competitor mRNA, the export of 32p. 
labeled DHFR mRNA was efficiently inhibited, showing 
that the mRNA export pathway was saturated (Figure 6, 
lanes 13-16). Under the same conditions, however, Rev- 
mediated export of pAd46 RNA was only slightly affected 
(Figure 6, lanes 13-16). In other experiments, mRNA com- 
petitor had no effect on the Rev-mediated export of pAd46, 
and it is possible that the effect observed in this case may 
be the result of a small fraction of pAd46 RNA not being 
DHFR 
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U6 
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~ ,  , f  7 ,  
N C N C N C N C 
+ 
1 2 3 4 5 6 7  
+Rev 
-competitor +competitor 
0,5h  2h  O,Sh 2h  
N C N C N C N C  
t 
[ 
9 10 11 12 13 14 15 16 
Figure 6. Rev-Mediated Export of RRE-Containing RNAs Was Not 
Saturable by an Excess of mRNA Competitor 
A mixture of a2P-labeled DHFR mRNA, pAd46 RNA, and U6 RNA (all 
RNAs mTG capped) was injected into oocyte nuclei either without 
(lanes 1-8) or with (lanes 9-16) a 10-fold molar excess of Rev protein. 
In experiments shown in lanes 5-8 and 13-16, 0.4 pmol of unlabeled 
DHFR mRNA competitor was also coinjected. Oocytes were analyzed 
as described in Figure 1. Abbreviations: N, nuclear; C, cytoplasmic. 
saturated with Rev and therefore leaving the nucleus by 
the mRNA export pathway. Because the saturation of the 
mRNA export pathway did not affect Rev-dependent RNA 
export and vice versa, both pathways require different lim- 
iting factors and are therefore mechanistically different. 
BSA-R Inhibits the Nuclear Export of 5S rRNA 
and Spliceosomal snRNAs 
We next asked whether factors required for the export of 
other cellular RNAs were affected by Rev. Specific export 
factors have been shown to be required for the export of 
spliceosomal snRNAs, 5S rRNA, tRNA, and rRNAs in the 
form of ribosomal subunits (Zasloff, 1983; Khanna-Gupta 
and Ware, 1989; Bataille et al., 1990; Jarmolowski et al., 
1994). 32P-labeled tRNA s+', U1ASm, 5S rRNA, and (as a 
control) DHFR mRNA were injected into the nucleus of 
oocytes, and export was studied either in the presence or 
absence of an excess of BSA-R or BSA-M competitor. The 
UI~Sm mutant RNA was chosen to study snRNA export 
since this RNA is exported as efficiently as wild-type U1 
RNA but is unable to reenter the nucleus as a result of 
the absence of an Sm site (Harem and Mattaj, 1990; Jar.- 
molowski et al., 1994). 
In the absence of competitor (Figure 7A, lanes 1-4), 
U1ASm and DHFR mRNA were almost quantitatively ex- 
ported within 4 hr, and approximately 50% of each was 
exported after 2 hr. Export of tRNA was much faster: after 
1 hr, transport was complete, and after 30 rain, more than 
60% of the tRNA had left the nucleus. Export of 5S rRNA 
was slower, and the absolute rate depended greatly on 
the batch of oocytes used. In most cases, approximately 
70% of the injected 5S rRNA was exported within 4 hr, 
Cell 
480 
A 
+SSA-M +BSA-R 
2hrs  4hrs  2hrs  4hrs  2hrs  4hrs  
N C N C N C N C N C N C 
0 .5h  lh  0 .5h lh  0 .5h l h  
N C N C N C N C N C N C 
1 2 3 4 5 6 7 8 9 10 11 12 
U1ASm 
5S rRNA 
U6 
tRNA 
B 
i 
¢~ • - Competitor 
I~" [ ]  + BSA-R 
°~ [ ]  -BSA-M 
90 min 180 min 
T ime 
Figure 7. Saturation of Rev-Mediated Export Inhibits 5S rRNA and 
U1ASm Export but Does Not Affect he Export of tRNA or Ribosomes 
(A) 32P-labeled in vitro transcribed DHFR mRNA, U1ASm (both mTG 
capped), 5S rRNA, and tRNA were injected into nuclei of o cytes along 
with either water (lanes 1-4), BSA-M (lanes 5-8), or BSA-R (lanes 
9-12) at concentrations of 10 mg/ml. The nuclear export of DHFR 
mRNA, U1ASm, and 5S rRNA was analyzed after 2 and 4 hr; the 
nuclear export of tRNA was analyzed after 30 min and 1 hr. Analysis 
of RNA was carried out as described in the legend to Figure 1.Even 
higher amounts of BSA-R competitor (up to 30 mg/ml was tested) 
showed identical results. Abbreviations: N, nuclear; C, cytoplasmic. 
(B) 3~P-labeled ribosomes purified from cultured HeLa cells were in-
jected into the nucleus of oocytes (5 ng of ribosomes per oocyte) either 
without competitor or with 10 mg/mi BSA-R or BSA-M competitor. Ex- 
port was analyzed after 90 and 180 min by quantitation ofautoradio- 
graphs containing the radiolabeled 28S and 18S rRNA after separation 
on a denaturing el. Average values for each timepoint are shown. 
Percent ransport indicates the amount of stable rRNA that was ex- 
ported at the indicated timepoint. 
whereas after 2 hr, only about 20% was found in the cyto- 
plasm (Figure 7A, lanes 1-4). When the same RNAs were 
injected along with an excess of either BSA-R competitor 
or BSA-M control conjugates, the xport kinetics of DHFR 
was unaffected, which confirmed the data described 
above (Figure 7A, lanes 5-12). Similarly, the export of 
tRNA was not specifically affected by the BSA-R competi- 
tor. In contrast, the export of both 5S rRNA and U1ASm 
RNA was almost entirely inhibited by BSA-R coinjection 
even after 4 hr incubation (compare lanes 1-8 with lanes 
9-12 in Figure 7A). In additional experiments, we observed 
that the export of not only U1ASm but also of all other 
spliceosomal m~G-capped snRNAs was strongly inhibited 
by BSA-R (data not shown). 
To test whether the export of ribosomal subunits was 
affected when Rev-mediated export was saturated, we in- 
jected 32P-labeled ribosomes isolated from HeLa cells into 
the nucleus of oocytes either without competitor or along 
with BSA-R or BSA-M (Figure 7B). Neither BSA-R nor 
BSA-M had any specific effect on the export kinetics of 
ribosomes (Figure 7B), suggesting that, like cellular 
mRNAs and tRNAs, ribosomal subunits do not leave the 
nucleus via the pathway that can be saturated by injection 
of BSA-R. 
Discussion 
tn this work we have investigated the mechanism of HIV-1 
Rev-mediated RNA export. Using an approach similar to 
that which led to the identification of a receptor that medi- 
ates protein import into the nucleus, the so-called nuclear 
localization signal receptor (Goldfarb et al., 1986; Powers 
and Forbes, 1995), we found that a conjugate between 
BSA and nine amino acids from the activation domain of 
Rev inhibited Rev-mediated export. On the basis of the 
trans-dominant negative phenotype of Rev mutants in the 
activation region, Malim et al. (1989b) previously predicted 
the existence of a trans-acting cellular cofactor involved 
in Rev-mediated RNA export, and the evidence presented 
here strongly supports the existence of such a factor. Fur- 
thermore, it can be concluded from our competition experi- 
ments that the activation domain alone is sufficient o inter- 
act with this cofactor. Other Rev domains such as the 
RNA-binding domain or the multimerization domain are 
not essential for this interaction. It has previously been 
shown that multimerization is essential for Rev function 
(Malim et al., 1989a). We note that the BSA-R conjugates 
used here carried roughly 20 peptides. It will be of interest 
to determine whether conjugates carrying one or a few 
peptides will be exported. It may be that a high local con- 
centration of Rev NESs will be required for function. 
We observed that not only BSA-R but also a BSA conju- 
gate harboring peptides from the HTLV-I Rex activation 
domain inhibited Rev-mediated export efficiently, support- 
ing earlier suggestions that the activation domains of these 
proteins are functionally similar (Rimsky et al., 1988). Our 
data further suggest that both proteins interact with a com- 
mon factor that mediates the export of the RNAs of these 
retroviruses that carry a binding site for the respective 
protein. In fact, this cellular cofactor might also be respon- 
sible for the RNA export of other complex retroviruses that 
express Rev-like proteins. It will be interesting to deter- 
mine whether the export of unspliced transcripts of Ma- 
son-Pfizer monkey virus, which is the only retroviral case 
described so far that uses a cellular RNA-binding factor 
to promote the export of its unspliced transcripts (Bray et 
al., 1994), also accesses the same pathway as RRE- 
containing HIV-1 transcripts. 
Probably the most revealing experiment for the action 
of Rev in RNA export was the demonstration that the acti- 
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vation domain, when conjugated to BSA, was able to direct 
nuclear export of the conjugate efficiently. Previous work 
had shown that Rev shuttles rapidly between the nucleus 
and the cytoplasm, even in the absence of RRE-containing 
RNA, making it possible that Rev would harbor a signal 
for nuclear export (Meyer and Malim, 1994; Kaltand et al., 
1994; Wolff et al., 1995). Definition of the Rev activation 
domain as an NES underlines the bifunctional nature of 
the Rev protein, with one functional domain being respon- 
sible for RNA binding, multimerization, and nuclear import 
while the other is essential for RNA export. 
Importantly, the Rev NES not only facilitates nuclear 
export in oocytes but also in cultured human somatic 
(HeLa) cells. Similar export systems that recognize the 
NES in both organisms and have been conserved in evolu- 
tion are therefore likely to exist. Interestingly, BSA-R did 
not localize to nucleoli in HeLa cells. This suggests that 
the interaction between the NES and the cellular cofactor 
probably takes place predominantly in the nucleoplasm 
and that the localization of Rev to nucleoli is not of signifi- 
cance for its export function (Malim et al., 1989a; Kalland 
et al., 1994). 
Our findings reveal the mechanism of a viral strategy 
to transport intron-containing pre-mRNA or mRNA mole- 
cules from the nucleus to the cytoplasm. Most surprisingly, 
the limiting factors that are involved in the export of cellular 
mRNAs appear not to be required for Rev-mediated ex- 
port. This result is unexpected since the viral RNAs that 
utilize Rev for their export in HIV-1 infected cells, although 
unspliced, are in fact mRNAs. On the other hand, BSA-R 
strongly inhibited U snRNA and 5S rRNA export as well 
as Rev-mediated RNA export, arguing that there must be 
a common factor required for the export of these RNA 
species, It is not possible from the data presented to deter- 
mine unequivocally whether the difference observed be- 
tween Rev-mediated U snRNA and 5S rRNA export on 
the one hand and mRNA, tRNA, and ribosomal subunit 
export on the other is qualitative or quantitative. Although 
the model that best fits our data is that the latter group of 
RNPs do not interact with the same factor as the Rev 
activation domain during their export, it remains possible 
that all the RN Ps do interact with one factor but with widely 
differing affinities, such that the Rev peptide can only com- 
pete with some RNPs for this interaction. 
Because coinjection of quantities of U snRNAs sufficient 
to saturate export do not affect 5S rRNA export and be- 
cause 5S rRNA export could not be saturated at the high- 
est concentrations tested, it was previously concluded that 
different limiting factors must be required for the export 
of these two types of RNA (Jarmolowski et al., 1994). One 
interpretation of the data presented here in relation to 
these previous findings is that BSA-R titrates a common 
factor that acts further downstream in the export process 
as compared with the factor that is titrated at high U snRNA 
concentrations, i.e., the cap-binding complex (Jarmolow- 
ski et al., 1994; Izaurralde et al., 1995). In other words, the 
competition experiments can most easily be interpreted to 
suggest that U snRNAs and 5S rRNA, prior to their export, 
bind proteins that are functionally equivalent o Rev and 
HIV- I  Rev  LPP  LER LTL  D -84  
X .L .  TF I I IA  L -V  LDK LT I  Q c - te rm.  
B .A .  TF I I IA  LPV L~.N LTL  K c - te rm.  
H. TF I I IA  LST  VAV LTL  G c - te rm.  
Figure 8. Sequence Comparison of the Activation Domain of HIV-1 
Rev with the Carboxy-Terminal Sequences of TFIIIA from X. laevis, 
Bufo americanus, and Human 
Conserved residues are indicated in bold letters. Abbreviations: XL, 
X. laevis; BA, B. americanus; H, human; c-term., carboxy-terminal. 
interact with the same cellular export factor. Interestingly, 
TFIIIA, a protein implicated in the export of 5S rRNA (Gud- 
dat et al., 1990), contains a sequence that is highly homolo- 
gous to the Rev activation domain (Figure 8). This se- 
quence may be involved in the proposed interaction. 
Schmidt-Zachmann et al. (1993) reported that proteins 
do not absolutely require positively acting export signals 
for their transport from the nucleus to the cytoplasm, al- 
though they noted that export in the absence of such sig- 
nals exhibited slow kinetics. For the proteins they studied, 
export from the nucleus was found to be predominantly 
limited by nuclear retention. Our data show that active and 
hence signal-mediated nuclear export processes do in fact 
exist. The rate of BSA-R export is much faster than the 
export of NES-lacking proteins, implying that the two 
classes of protein are exported by processes that are 
mechanistically different. One possible explanation for the 
observation that Rev requires an active export signal while 
some proteins do not is that Rev exports RNA molecules 
that are normally retained in the nucleus. Rev export- 
promoting activity therefore has to be dominant over nu- 
clear retention. Proteins whose export rate is determined 
by the degree of their nuclear retention are unlikely to be 
able to accomplish this task. The export of different cellular 
RNA species might in general depend on proteins that 
harbor positively acting export signals since it has been 
shown that their export is generally saturable and hence 
receptor mediated (reviewed by Izaurralde and Mattaj, 
1995). Positively acting export signals might therefore be 
located on other possible mediators of RNA export, such 
as the shuttling protein hnRNP A1 (PiSoI-Roma and Drey- 
fuss, 1991, 1992), TFIIIA, ribosomal protein L5 (Guddat 
et al., 1990), and the nuclear cap-binding protein complex 
(Izaurralde et al, 1995). 
An implication of our results is that similar signals can 
(and therefore may) be utilized to direct the active export 
of both proteins and RNPs from the nucleus. It may be 
that the export of many different macromolecules from the 
nucleus might therefore be mediated by a small number 
of signal-receptor systems, but further study will be re- 
quired to determine whether the situation is, in fact, this 
simple. 
Experimental Procedures 
Synthesis of RNA In Vitro 
Plasmids pAd46, pAd48, DHFR, U1ASm, 5S, tRNA, and U6 were 
described previously (Fischer et al. 1994a; Jarmolowski et al., 1994). 
Ptasmid DNA was linearized with restriction endonuclease Scal 
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(pAd46), BamHI (pAd48, U1ASm, and U6), Dral (5S), or BstNI (tRNA) 
and used as template for transcription in vitro with T7 RNA polymerase 
(Fischer et al., 1994a). Template DNA was eliminated after transcrip- 
tion by a 15 min incubation at 37°C with 1 i11 of DNase I (1 U/#.I; 
Promega, RQ grade). Labeled RNA was extracted with phenoI-CHCI3, 
precipitated with ethanol, and redissolved in Rev-binding buffer (see 
below) immediately before use for microinjections. Preparation of in 
vivo labeled HeLa ribosomes was carried out as described previously 
(Bataille et al., 1990). 
Microinjection into Oocytes and Analysis of Injected RNA 
and Protein 
Ovaries of X. laevis females were cut into small pieces and incubated 
for 3-5 hr in modified Barth's solution (Hamm and Mattaj, 1990) con- 
taining 0.2% collagenase type II (Sigma). Defolliculated stage V and VI 
oocytes were collected, stored in small fractions, and used for injection 
experiments within the following 2 days. 
For injection of Rev-RNA complexes, 32P-labeled RRE-RNA (0.5 x 
106 to 1 x 106 cpm/#.l; total concentration of 0.7 p.M) was incubated 
for 30 rain on ice in Rev-binding buffer (1 M NaCt, 20 mM HEPES- 
KOH [pH 7.9], 2.5 mM MgCI2, 0.5 mM EDTA, 10% glycerol, and 1 mM 
DTT) in the presence of a 20-fold molar excess of recombinant Rev 
protein (14 #M) to allow formation of complexes (Fischer et al., 1994a). 
32P-labeled U6 RNA and a 10 mg/ml solution of dextran blue were 
added to all mixtures to monitor the site of injection; 15 nl of solution 
was injected per nucleus, and oocytes were then incubated at 20°C. 
Oocytes were dissected manually, and each fraction was analyzed as 
described previously (Hamm and Mattaj, 1990). Injection of iodinated 
BSA-R and BSA-M conjugates was carried out as described for RNAs. 
Oocytes were dissected in TNE medium (100 mM NaCI, 1 mM EDTA, 
and 10 mM Tris-HCI [pH 7.4]). Nuclei were fixed and pelleted in 95% 
ethanol. The cytoplasms were homogenized in TNE, the insoluble 
fraction removed by centrifugation, and proteins in the supernatant 
precipitated with 5 vol of acetone. Precipitated proteins were dissolved 
in protein sample buffer and fractionated by SDS-PAGE (Laemmli, 
1970). Gels were subsequently fixed in 40% MeOH, 10% acetic acid, 
dried, and exposed. 
Preparation of BSA-Peptide Conjugates 
BSA (5 mg) (Boehringer Mannheim) was dissolved in 1 ml of phos- 
phate-buffered saline (PBS) (pH 7.4) and incubated for 1 hr at 20°C 
with 8 mg of sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohex~.ne-1- 
carboxylate (sulfo-SMCC) (Pierce Chemical), BSA was subsequently 
separated from the unreacted sulfo-SMCC by passing the whole mix- 
ture over a Sephadex P-10 column (Pharmacia). The purified BSA 
was then mixed with 5 mg of the desired peptide (BSA-R, BSA-M, or 
BSA-Rex), dissolved in 1 ml of PBS (pH 6.5), and incubated at 4°C 
overnight. Conjugation was assessed by SDS-PAG E, and BSA-pep- 
tide conjugates were subsequently concentrated to 20 mg/ml in a Mini- 
con 30 concentrator (Amicon). For fluorescent labeling, BSA-R and 
BSA-M were incubated for 60 min in buffer containing 50% dimethyl- 
sulfoxide, 50 mM potassium phosphate buffer (pH 6.8), and a 300-fold 
molar excess of fluorescein isothiocyanate or N-(resorufin-carbonyl)- 
N'-(iodoacetyl) piperazine (Boehringer Mannheim). Conjugates were 
purified and concentrated by P-10 column chromatography and centrif- 
ugation in a Centricon C-10 unit (Amicon). 
Microinjection into Somatic Cells 
HeLa cells were grown to 80% confluence on CELLocate microgrid 
coverslips (Eppendorf). Microinjection was carried out as described by 
Fischer et al. (1994b). The amount of microinjected fluorescent-labeled 
BSA-R and BSA-M conjugates varied between 5 x 105 and 10 x 102 
molecules per cell (100 fi). In competition experiments, a 20-fold ex- 
cess of BSA-R or BSA-M was coinjected. Cells were incubated in 
ice-cold 3O/o paraformaldehyde in PBS (pH 7,4) for 15 min. Fixed cells 
were mounted using Fluorep mounting medium (BioMerieuex), and 
photographs were taken on a Leitz Aristoplan microscope. 
Radioiodination of Proteins 
For radioiodination of proteins, a PBS solution containing 50 p.g of 
either BSA-R or BSA-M, 2 mCi of [~2Sl]Nal, and one lODe-Bead iodin- 
ation reagent (Pierce) was mixed gently at 20°C for 3 min. Nonincorpo- 
rated ~51 was subsequently removed by concentration of the reaction 
mixture in a Centricon C-10 unit (Amicon). The solution injected into 
oocytes contained approximately 0.25 mg/ml iodinated protein. 
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